1. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013;58:428-438.
2. Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 2016;151:70-86.
3. D’Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol 2017;24:31-37.
4. D’Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol 2019;70:379-387.
5. Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment PharmacolTher 2019;49:492-505.
6. Fourati S, Rodriguez C, Hézode C, Soulier A, Ruiz I, Poiteau L, et al. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. Hepatology 2019;69:513-523.
7. Jeong Y, Jin B, Lee HW, Park HJ, Park JY, Kim DY, et al. Evolutionand persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures. J Viral Hepat 2018;25:1251-1259.
8. Aghemo A, Piroth L, Bhagani S. What do clinicians need to watch for with direct‐acting antiviral therapy? J Int AIDS Soc 2018;21 Suppl 2:e25076.
9. European Association for the Study of the Liver. EASL recommendationson treatment of hepatitis C 2018. J Hepatol 2018;69:461-511.
10. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018;67:1477-1492.
11. Younossi ZM, Stepanova M, Charlton M, Curry MP, O’Leary JG, Brown RS, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol 2016;1:122-132.
13. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017;376:2134-2146.
14. Saxena V, Chamberland S, Hurley L, Lai JB, Truong E, Marcus J, et al. Real-world safety and effectiveness of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir in hepatitis C infected patients [Abstract]. Hepatology 2018;68:418A-419A.
15. Bacon BR, Curry MP, Flamm SL, Milligan S, Tsai N, Wick N, et al. Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in care of chronic hepatitis C patients; clinical practice experience from the TRIO network [Abstract]. Hepatology 2018;68:419A.
16. Belperio P, Bakckus L, Shahoumian T, Loomis T, Mole L. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 treatment experiencedpatients with hepatitis C [Abstract]. Hepatology 2018;68(Suppl 1):S227.
18. Sulkowski MS, Lok AS, Willner IK, Reddy KR, Shiffman ML, Hassan MA, et al. High efficacy of glecaprevir/pibrentasvir in patients with chronic HCV GT1 infection who failed prior treatment with NS5A-inhibitor plus sofosbuvir regimens [Abstract]. Hepatology 2018;68:141A-142A.
20. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, et al. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol 2017;2:427-434.
21. Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman CAM, Davis MN, et al. Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen. Hepatology 2017;66:1083-1089.